Asciminib hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for asciminib hydrochloride and what is the scope of patent protection?
Asciminib hydrochloride
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Asciminib hydrochloride has eighty-four patent family members in forty-nine countries.
One supplier is listed for this compound.
Summary for asciminib hydrochloride
International Patents: | 84 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 16 |
Patent Applications: | 2 |
DailyMed Link: | asciminib hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for asciminib hydrochloride
Generic Entry Date for asciminib hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for asciminib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sarit Assouline | Phase 3 |
Novartis | Phase 3 |
Augusta University | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for asciminib hydrochloride
US Patents and Regulatory Information for asciminib hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-003 | Apr 18, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-003 | Apr 18, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-001 | Oct 29, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-002 | Oct 29, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novartis | SCEMBLIX | asciminib hydrochloride | TABLET;ORAL | 215358-003 | Apr 18, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for asciminib hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Philippines | 12014502531 | BENZAMINE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ⤷ Sign Up |
Slovenia | 2861579 | ⤷ Sign Up | |
Australia | 2013261130 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | ⤷ Sign Up |
Mexico | 2014013376 | DERIVADOS DE BENZAMIDA PARA INHIBIR LA ACTIVIDAD DE ABL1, ABL2, Y BCR-ABL1. (BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1.) | ⤷ Sign Up |
Denmark | 2861579 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for asciminib hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2861579 | CR 2022 00046 | Denmark | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SASOM ASCIMINIB HYDROKLORID; REG. NO/DATE: EU/1/22/1670 20220826 |
2861579 | 122022000072 | Germany | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON, WIE ZUM BEISPIEL ASCIMINIBHYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1670 20220825 |
2861579 | C202230056 | Spain | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, TAL COMO HIDROCLORURO DE ASCIMINIB; NATIONAL AUTHORISATION NUMBER: EU/1/22/1670; DATE OF AUTHORISATION: 20220825; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1670; DATE OF FIRST AUTHORISATION IN EEA: 20220825 |
2861579 | C02861579/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68441 09.06.2022 |
2861579 | 2290039-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS ASCIMINIB HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1670 20220826 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |